Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 5,425
- Institution
- Phramongkutklao Hospital
External Links
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.